August 17, 2016 – The Institute for Clinical and Economic Review (ICER) will develop a report assessing the comparative clinical effectiveness and value of abuse-deterrent opioids for pain management. The report will form the basis of a March 2017 meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC).
Deaths related to opioid use disorder continue to be a primary public health concern. In an effort to help curb the epidemic, drug manufacturers are developing abuse-deterrent opioids for patients in need of opioid pain medication. To date, the Food and Drug Administration has approved a number of abuse-deterrent opioids and is expected to make approval decisions on several new formulations this fall. ICER’s report will review several of these new and emerging medications with the goal of providing clarity on how effectively these drugs work to reduce misuse of opioids and its many consequences, including overdose and opioid-related death.
A three-week “Open Input” period begins today, and comments on the topic will be accepted from any and all interested stakeholders. The Open Input period is intended to allow stakeholders to share key information relevant to the development of ICER’s scope and evidence report. During this time, ICER will also contact key patient groups and clinical experts to gain further insights.
For more information about the Open Input period, including a further explanation of the types of information that may be most helpful to development of the report, visit ICER’s website. There are no page limits to Open Input submissions, and input received will be incorporated throughout report development. All input can be emailed to publiccomments@icer-review.org and must be received by 5PM ET on Wednesday, September 7th in order to be considered.
A Draft Scoping Document, which will provide more detail on ICER’s proposed scope for the review, will be available on or about September 8, 2016.
During the March 2017 meeting of the New England CEPAC, the independent Council will deliberate and vote on the comparative clinical effectiveness and value of the treatments included in this review. The Council will discuss the implications of the votes for policy and practice with a roundtable of experts in the field to provide guidance to patients, clinicians, insurers, and policymakers confronted with decisions on use of abuse-deterrent opioids.
Key Dates
Key dates for the development of the report, including formal opportunities for stakeholder engagement, are as follows:
Topic announcement: August 17, 2016 Open Input Period: August 17, 2016-September 7, 2016 Draft Scoping Document posted: September 8, 2016 Public comment on Draft Scoping Document: September 8, 2016- September 28, 2016 Final Scoping Document posted: October 6, 2016 Draft Evidence Report and Draft Voting Questions Posted: January 25, 2017 Public Comment on Draft Evidence Report and Draft Voting Questions: January 25, 2017-February 22, 2017 Evidence Report and Revised Voting Questions Posted: March 9, 2017 Public Meeting of the New England CEPAC: March 23, 2017 Final Report Posted: March 30, 2017
News 
Market Data 
Discover 
